Project Grant RF1AG077484
Award Date
6/1/22
Completion Date
5/31/25
Dollars Obligated
$4M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $1,100,000 in funding to the University of Texas Medical Branch at Galveston to support research into the mechanisms of pathological tau spreading in Alzheimer's disease. The project aims to determine how amyloid-beta oligomers modulate the binding and internalization of toxic tau oligomers to vulnerable synapses, which is a key component of the trans-synaptic spread of tau...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $431,750 will support the delivery of a novel immuno-gene therapy for treating tauopathy, a group of neurodegenerative conditions including Alzheimer's disease. The award will fund the development and testing of a recombinant adeno-associated virus (rAAV) expressing a single-chain fragment variable (scFv) antibody targeting oligomeric tau, a toxic tau species believed to be a key...
The National Institute on Aging (NIA) awarded a $1,698,335 Project Grant (CFDA 93.866 - Aging Research) to The Washington University to develop self-assembling peptide nanofiber vaccines targeting amyloid-beta and tau proteins for the treatment of neurodegenerative disorders like Alzheimer's disease and frontotemporal dementia. The key products and services to be delivered under this 5-year grant include: 1) assessing the toxicity and seeding capacity of the peptide nanofibers bearing...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $999,822 to Aeton Therapeutics Inc. to develop an acetylated tau immunotherapy for the treatment of Alzheimer's disease. The project aims to evaluate the effectiveness and safety of the lead antibody candidate AT-01 in vitro and in mouse models, benchmarking its performance against another anti-tau monoclonal antibody. Specific goals include assessing AT-01's ability to reduce tau pathology...
The National Institute on Aging (NIA) awarded a $320,000 Project Grant (CFDA 93.866) to the University of Texas Medical Branch at Galveston (UTMB) to study the role of alternative polyadenylation (APA) regulation in Alzheimer's disease (AD). The project aims to comprehensively profile APA transcripts and gene expression in neurons expressing wild-type and mutant tau proteins, which are implicated in AD pathogenesis. Using the innovative Poly(A)-ClickSeq (PAC-Seq) technology, the researchers will...
The National Institute on Aging (NIA) awarded a $766,133 Project Grant (CFDA 93.866 - Aging Research) to the University of Texas Health Science Center at Houston (UTHealth) to conduct research on the mechanisms of amyloid-related imaging abnormalities (ARIA) following anti-amyloid immunotherapy for Alzheimer's disease. The project aims to: Determine the elimination pathway and clearance mechanism of chimeric anti-amyloid antibodies in Alzheimer's disease mouse models. Examine how ARIA events...
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD). The project aims to develop new...
This $553,998 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to develop a peptide-based platform for the discovery of functional tau epitopes related to neurodegenerative diseases like Alzheimer's. The key products and services include: Diversity-oriented synthesis of a library of conformationally constrained peptide macrocycles ("mini-taus") that mimic the beta-arch structure of pathological tau fibrils. These mini-taus will...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
This $1,015,163 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel in vivo CRISPR/Cas9 screening method to identify regulators of tau protein levels in the mouse brain. The two-year award to Baylor College of Medicine will allow the researchers to bypass labor-intensive in vitro processes and directly study tau regulation within a physiologically relevant mouse model of Alzheimer's disease. The goal is to gain comprehensive...